A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annnual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif) in Treatment-Naive Patients with Relapsing Multiple Sclerosis

  • Houff, Sidney (PI)

Grants and Contracts Details

StatusFinished
Effective start/end date4/4/0812/31/09